Patent · US Active

WRN inhibitors

US12344609B2 · kind B2 · utility

0Cited by

2References

26Claims

0Family size

Assignee

Nimbus Wadjet, Inc. · US

Inventors

Derun Li · Dedham, US
Angela V. West · Watertown, US
Justin Andrew Caravella · Cambridge, US
Nathan Genung · Boston, US
Florian Bartels · Berlin, DE
Robert L. Dow · Waterford, US
Silvana Marcel Leit de Moradei · Burlington, US
Nikolay Sitnikov · Berlin, DE

Key dates

Filing date	Jan 27, 2025
Grant date	Jul 1, 2025
Priority date	—
Expiry date	Jan 27, 2045

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure is directed to compounds of Formula II-e: and pharmaceutically acceptable salts thereof, and compositions thereof, as well as methods of treatment of cancers such as those involving WRN protein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.